Recent advances in oxazolidinones as antituberculosis agents

Future Med Chem. 2022 Aug;14(15):1149-1165. doi: 10.4155/fmc-2022-0079. Epub 2022 Jul 22.

Abstract

Tuberculosis (TB) is an infectious and fatal disease caused by Mycobacterium tuberculosis (Mtb) and remains a serious public health threat; therefore, the development of new antitubercular agents is a priority for the World Health Organization's End TB strategy and the United Nations' Sustainable Development Goals to eradicate TB. Oxazolidinones are a class of synthetic antibacterial agents with a distinct mode of action developed for the treatment of Gram-positive bacterial infections. Many oxazolidinones exhibit good activity against Mtb, and some are currently in clinical trials for multidrug-resistant TB and extensively drug-resistant TB therapy. In this review, the mechanism of action, activity and toxicity of oxazolidinones and recent progress in the research and development of oxazolidinones as anti-TB agents are summarized.

Keywords: Mycobacterium tuberculosis; antituberculosis agents; mechanism of action; oxazolidinones; toxicity.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antitubercular Agents / pharmacology
  • Antitubercular Agents / therapeutic use
  • Humans
  • Mycobacterium tuberculosis*
  • Oxazolidinones* / pharmacology
  • Oxazolidinones* / therapeutic use
  • Tuberculosis* / drug therapy
  • Tuberculosis* / microbiology
  • Tuberculosis, Multidrug-Resistant* / drug therapy

Substances

  • Antitubercular Agents
  • Oxazolidinones